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Introduction {#sec1}
============

Medullary Thyroid Carcinoma (MTC) originates from neural crest-derived parafollicular C-cells and can occur in hereditary (25%) or sporadic forms (75%) ([@bib23]). Germline-activating *RET* mutations are found in 95%--98% of hereditary MTC, whereas somatic *RET* mutations are present in 25%--40% of sporadic MTC (sMTC) ([@bib7], [@bib13], [@bib23], [@bib32]). Several types of somatic *RET* mutations have been reported in sMTC, with the most common mutation occurring in codon M918 within exon 16, which is present in up to 90% of *RET*-positive cases, followed by mutations in codon C634 within exon 11 ([@bib15], [@bib17], [@bib31]).

The presence of *RET* somatic mutations in sMTC has been shown to have a negative prognostic value ([@bib14]). In addition to point mutations, aneuploidy of chromosome 10 and *RET* gene amplification have been described in MTC cases, prevalently in cases with a somatic *RET* mutation ([@bib11]).

Recently, activating point mutations in *RAS* genes (*H-*, *K-*, and *NRAS*) has been described in *RET*-negative sMTC, with a variable percentage depending on the different series and screening techniques employed ([@bib1], [@bib4], [@bib10], [@bib25], [@bib26]). *RAS* gene point mutations in MTC mainly occur in *H-* and *KRAS*, and they are usually mutually exclusive with *RET* mutations. In our previous study, we found that patients harboring *RAS* mutations showed a better prognosis than those harboring *RET* mutations or presenting no mutations ([@bib10]).

Despite the presence of *RET* and *RAS* somatic mutations, 20--50% sMTC are still orphans of a genetic driver. Assessing the mutational status, especially for the *RET* gene, is crucial for targeted therapies with tyrosine kinase inhibitors currently employed, such as vandetanib and cabozantinib ([@bib16], [@bib42]), and the discovery of new oncogene alterations remains crucial to individuate novel targets for this type of therapy.

The recent advent of next-generation sequencing (NGS) techniques has dramatically changed our understanding of cancer genomics with the discovery of novel genetic alterations responsible for the pathogenesis of several cancer types ([@bib3]).

In these recent years, NGS has been applied in endocrine research as well ([@bib30]), and several reports have been published for MTC, in some cases using a whole-exome approach ([@bib1], [@bib8]) but mainly targeted sequencing ([@bib19], [@bib21], [@bib35], [@bib41]). According to the results reported in these studies, despite the presence of some rare events present in a few cases, the common occurrence of mutually exclusive *RET* and *RAS* mutations has been confirmed to be the main pathogenic signature of sMTC. The few novel alterations found in these studies represent more likely a "private" mutation of that specific tumor than significantly recurrent genetic alterations. The major limits of these previous studies are the relative low number of cases analyzed and few data about the correlation between the mutations and clinical and pathological features of the tumors.

We aimed to analyze a large series of sMTC by NGS targeted sequencing using a thyroid-specific gene mutation panel to delineate their mutational landscape and correlate the molecular data with the pathological characteristics of the tumors and with both the clinical features and outcome of patients affected with sMTC.

Results {#sec2}
=======

Sequencing Metrics and Overview of Gene Alterations Detected by NGS Targeted Sequencing {#sec2.1}
---------------------------------------------------------------------------------------

Of 209 cases studied, 28 were excluded as not informative due to technical reasons or insufficient quality of data obtained. Informative sequencing data were then obtained for 181/209 (86.6%) sMTC. The mean value of the variant vertical coverage obtained was 2,038X (median, 2,049.5; range, 117.7--5,713), and the mean number of reads for the sample was 385,564.1 (median, 396,496.5; range, 21,198--1,744,507).

In total, 166 genetic alterations were detected in 148 sMTC cases ([Table S1](#mmc1){ref-type="supplementary-material"}). In particular, we found 152 single-nucleotide variations and 14 indels: 107/166 (64.5%) were found in the *RET* protooncogene, 48/166 (28.9%) in the three *RAS* genes (*HRAS*, *KRAS*, *NRAS*), 5/166 (3%) in the *MET* gene, 2/166 (1.2%) in the *TP53* gene, 1/166 (0.6%) in the *TSH* receptor (TSHR) gene, 1/166 (0.6%) in the *EIF1AX* gene, 1/166 (0.6%) in the *CHK2* gene, and 1/166 (0.6%) in the*PPM1D* gene. One hundred fifty-four gene alterations were validated by Sanger direct sequencing and confirmed to be somatic, five were found to be germline, one was confirmed in tissue DNA, but blood was not available for germline validation, and six were not validated by Sanger direct sequencing due to low Variation Allele Frequency (VAF) values or for other technical reasons.

All the mutations that were previously detected by Sanger sequencing for somatic *RET* and *RAS* mutations were confirmed by NGS while in eight cases we observed a discrepancy with a previous negative result by Sanger and a positive one by NGS. This apparent discrepancy was due either to the low VAF that was under the detection limit of Sanger (\<20%) or bad Sanger sequencing quality.

Analysis of Genetic Alterations Occurring in sMTC Cases {#sec2.2}
-------------------------------------------------------

### General Distribution of Mutations {#sec2.2.1}

As shown in [Table S1](#mmc1){ref-type="supplementary-material"}, the number of cases harboring one or more genetic alterations was 148/181 (81.7%), whereas the remaining 33/181 (18.3%) did not carry any alteration targeted in our panel. In particular, 132/148 (89.2%) mutated cases harbored one single mutation, whereas 11/148 (7.4%) showed a heterogeneous pattern due to the presence of a somatic driver mutation coupled with one or more other somatic mutations and 5/148 (3.4%) harbored one somatic driver mutation coupled with a second germline mutation ([Table 1](#tbl1){ref-type="table"}).Table 1List of Cases Presenting Multiple Somatic Alterations and Somatic Coupled with a Germ-Line Alteration (in bold). Variant Allele Frequency (VAF) Values Are Reported in BracketsNoAlteration 1Alteration 2Alteration 3Alteration 441*RET* M918T (s) \[47.3%\]*RET* D925A (s) \[46.7%\]242*RET* M918T (s) \[32.2%\]*RET* R297H (s) \[11.8%\]196*RET* M918T (s) \[12.3%\]*RET* R833C (s) \[25.0%\]*RET* S891A (s) \[20.3%\]*MET* T1010I (n.v.) \[18.6%\]140*RET* M918T (s) \[39.0%\]*KRAS* K182E (n.v.) \[20.0%\]176*RET* C634W (s) \[17.3%\]*NRAS* A18V (s) \[7.5%\]253*RET* C634W (s) \[11.6%\]*MET* T1010I (s) \[50.1%\]132*RET* D898_E901del (s) \[30.9%\]*RET* S904P (s) \[30.8%\]169*RET* C620R (s) \[41.5%\]*MET* T1010I (n.v.) \[6.7%\]3*RET* C618G (n.v.) \[40.5%\]*TP53* R283C (n.v.) \[48.1%\]251*HRAS* G13R (s) \[23.3%\]*MET* T1010I (s) \[8.3%\]39*HRAS* Q61R (s) \[34.4%\]*RET* M918T (s) \[3.0%\]88*RET* M918T (s) \[19.7%\]***KRAS A130V (g) \[44*.*9%\]***91*RET* C634Y (s) \[37.3%\]***RET R215L (g) \[49*.*9%\]***201*RET* D898_E901del (s) \[26.6%\]***PPM1D K469E (g) \[37*.*5%\]***20*HRAS* Q61R (s) \[41.7%\]***MET T1010I (g) \[51*.*4%\]***52*TSHR* I630L (s) \[31.0\]***TP53 R158C (g) \[52*.*8%\]***[^4]

### Types of Mutations {#sec2.2.2}

Cases presenting *RET* somatic alterations as the driver were 101/181 (55.8%): in 88 cases as a single alteration and in 13 cases as multiple alterations. Cases presenting *RAS* mutations as the driver were 44/181 (24.3%): in 42 cases as a single mutation and 2 cases in association with either a somatic or germline *MET* T1010I mutation. Finally, 3/181 (1.6%) cases presented mutations in other genes (i.e., *CHK2* W114\*, *EIF1AX* G135A, and *TSHR* I630L) ([Table S1](#mmc1){ref-type="supplementary-material"}). The remaining 33/181 (18.3%) were negative for all alterations targeted in our panel.

### *RET* Mutations: Prevalence, Types, and Associations with Other Mutations {#sec2.2.3}

As shown in [Figure 1](#fig1){ref-type="fig"}, 60/148 (40.5%) mutated sMTC harbored the *RET* M918T mutation. In 54 cases, it was present as a single mutation; and in 6 cases, it was associated with other *RET* (n = 3) or *RAS* mutations (n = 3). The details of associated mutations are reported in [Table 1](#tbl1){ref-type="table"}. The *RET* gene C634 codon was mutated in 18/148 (12.2%) cases with different aminoacidic alterations ([Figure 1](#fig1){ref-type="fig"}). In 15 cases, it was present as a single mutation, whereas, in 3 cases, it was associated with other alterations. A *RET* indel was present in 14/148 (9.5%) cases ([Table S1](#mmc1){ref-type="supplementary-material"} and [Figure 1](#fig1){ref-type="fig"}): in 12 cases, it was present as a single mutation, while in 2 cases it was associated with other alterations. Additionally, 3/148 (2%) cases presented the C620R mutation, and one of them harbored a simultaneous *MET* T1010I mutation. Another 2/148 (1.3%) cases showed a C618R mutation, and one of them had a simultaneous *TP53* R283C mutation. Finally, 2/148 (1.3%) cases presented the *RET* S891A mutation, and 1/148 (0.7%) cases showed the *RET* C630R and 1/148 (0.7%) cases showed the *RET* S1024F mutation. Among cases harboring *RET* multiple mutations, cases n. 41 and 132 presented the *RET* M918T + D925A and *RET* D898_E902del + S904P mutations, respectively. The analysis of the specific sequencing reads associated with these mutations showed that they were very close and on the same allele (i.e., in *--cis*), likely consequent to a single mutational event (data not shown). A complete detailed description of these mutations is summarized in [Table S1](#mmc1){ref-type="supplementary-material"} and [Figure 1](#fig1){ref-type="fig"}.Figure 1Mutational Landscape of sMTCMutational profile of the 168 informative sMTC cases identified by NGS analysis. Each column corresponds to a single case. Genetic variations are listed on the left. The colored squares correspond to somatic mutations, whereas the black squares correspond to germline mutations, all validated by Sanger sequencing. Squares with a point-pattern represent mutations that were not validated by Sanger or not confirmed to be somatic or germline. See also [Table S1](#mmc1){ref-type="supplementary-material"}.

### *RAS* Mutations: Prevalence, Types, and Associations with Other Mutations {#sec2.2.4}

Alterations of the three *RAS* genes were present in 44/148 (29.7%) mutated cases. Of 148 sMTC cases, 31 (20.9%) were mutated in the *HRAS* gene and included 2 cases with a simultaneous somatic or germline *MET* T1010I mutation, respectively ([Figure 1](#fig1){ref-type="fig"}). Another 12/148 (8.2%) cases were positive in *KRAS*, and only 1/148 (0.7%) presented the *NRAS* Q61K mutation ([Table S1](#mmc1){ref-type="supplementary-material"} and [Figure 1](#fig1){ref-type="fig"}).

### Other Unconventional Mutations: Prevalence, Types, and Associations {#sec2.2.5}

Only 3/148 (2%) sMTC cases harbored single mutations in other genes belonging to our panel, such as *CHK2* W114\*, *EIF1AX* G135A, and *TSHR* I630L. The last case was also associated with a germline *TP53* R158C mutation. Although the *TSHR* I630L mutation has been validated as somatic, the other two mutations could not be, and consequently, we could not establish their potential driver role.

### Rare and Uncommon Mutations In the Analyzed Genes {#sec2.2.6}

As shown in [Table 2](#tbl2){ref-type="table"}, among the above-reported mutations, we found a series of 18 uncommon and/or novel alterations. With the exception of the somatic or germline *MET* T1010I mutation, which was present in five separate cases already harboring either *RET* or *RAS* alterations ([Table 3](#tbl3){ref-type="table"}), all the others were single mutations in single cases. Considering their rarity and according to the *in silico* analysis (i.e., Clinic Var and MutTaster prediction tests) and public database of known gene alterations (i.e., dbSNP and COSMIC and HGMD), we hypothesized that they could be private mutations whose driver role in the pathogenesis of the sMTC is unclear ([Table 3](#tbl3){ref-type="table"}).Table 2Details of Unconventional Alterations Found by NGS Targeted SequencingCaseGene MutationVAF (%)StatusdbSNP IDMAFCOSMIC ID *α* HGMD ID *β*ClinVar Prediction *γ* MutTaster Prediction *δ*Notes88*KRAS* c.389C \> T; p.A130V44.9Germ liners730880473\<0.01COSM4169153 ***α***Uncertain significance ***γ***Simultaneous *RET* M918T (s);\
reported as "neutral" ([@bib39])41*RET* c.2774A \> C; p.D925A46.7SomaticNovel--NovelDisease causing ***δ***Occurring in -*cis* with *RET* M918T (s)242*RET* c.890G \> A; p.R297H11.8SomaticNovel--NovelPolymorphism ***δ***Simultaneous *RET* M918T (s)196*RET* c.2497C \> T; p.R833C25Somaticrs377767422\<0.01CM068590 ***β***Likely pathogenic ***γ***Simultaneous *RET* M918T (s)20,169,196251,253*MET* c.3029C \> T; p.T1010IVariousSomatic; germ liners56391007\<0.01COSM707 ***α***\
CM118113 ***β***Conflicting results ***δ***176*NRAS* c.53C \> T; p.A18V7.5SomaticNovel--NovelDisease causing ***δ***Simultaneous *RET* C634W (s)91*RET* c.644G \> T; R215L49.9Germ liners748128929\<0.01--Polymorphism ***δ***Simultaneous *RET* C634Y (s)201*PPM1D* c.1405A \> G; p.K469E37.5Germ liners61756416\<0.01--Disease causing ***δ***Simultaneous *RET* E898_E901del (s); reported as "benign" in breast and ovarian cancer ([@bib34])132*RET* c.2710T \> C; p.S904P30.8SomaticNovel--NovelDisease causing ***δ***Occurring in -*cis* with *RET* E898_E901del (s)128*RET* c.1908_1909insTGCCG\
CACG; p.T636_V637delinsCRT35.4Somaticrs377767437--CI983210 ***β***Likely pathogenic ***γ***Described germ-line in MEN2A ([@bib20])122*RET* c.1886_1891delTGTGCG; p.L629_D631delinsH38.4SomaticNA--COSM27040 ***α***--Likely driver302*RET* c.1894_1902delGAGCT\
GTGC; p.E632_C634del42.9SomaticNovel--Novel--Likely driver252*RET* c.3071C \> T; p.S1024F17.6SomaticNovel--NovelDisease causing ***δ***Likely driver3*TP53* c.847C \> T; p.R283C48.1n.v.rs149633775\<0.01COSM10911 ***α***/CM041458 ***β***Conflicting results ***δ***Simultaneous *RET* C618G (s)52*TSHR* c.1888A \> C; p.I630L31Somatic----COSM26432 ***α***/CM100952 ***β***Disease causing ***δ***Simultaneous *TP53* R158C (g)52*TP53* c.472C \> T; p.R158C52.8Germinalrs587780068\<0.01COSM43848 ***α***/CM121763 ***β***Pathogenic ***γ***Simultaneous *TSHR* I630L (s)196*EIF1AX* c.404G \> C; G135A41.4n.v.NovelNovelDisease causing ***δ***198*CHK2* c.341G \> A; W114\*10.1n.v. in bloodNovelNovelDisease causing ***δ***[^5]Table 3List of Cases Presenting the *MET* T1010I Mutation in Association with *RET* or *RAS* Somatic MutationsN.Somatic MutationMET T1010I196*RET* M918T (s) \[12.3%\]\
*RET* S891A (s) \[20.3%\]\
*RET* R833C (s) \[25.0%\]*MET* T1010I (n.v.) \[18.6%\]253*RET* C634W (s) \[11.6%\]*MET* T1010I (s) \[50.1%\]169*RET* C620R (s) \[41.5%\]*MET* T1010I (n.v.) \[6.7%\]110*HRAS* Q61R (s) \[41.7%\]*MET* T1010I (g) \[51.4%\]251*HRAS* G13R (s) \[23.2%\]*MET* T1010I (s) \[8.3%\][^6][^7]

### TERT Promoter C228 and C250 Mutational Status {#sec2.2.7}

The sequencing data for the *TERT* promoter were available for 148/181 (81.8%) cases. Neither C228T nor C250T mutations were found in any of the studied cases.

### Whole-Exome Sequencing {#sec2.2.8}

The whole-exome sequencing (WES), despite the wide and deep analysis, did not reveal any other recurrent somatic mutation either in the four sMTC negative at the targeted sequencing or in those already known to be *RET* mutated.

Correlation of the Mutational Status of Primary sMTC with the Clinical and Pathological Features of the Patients {#sec2.3}
----------------------------------------------------------------------------------------------------------------

The 175/209 (83.7%) sMTC cases, whose primary tumor was analyzed, were divided into four categories depending on the mutational status (*RET* M918T, *RET* other, *RAS* mutations, and not *RET*/not *RAS*) and were correlated with the clinical and pathological features of the patients ([Table 4](#tbl4){ref-type="table"}). A statistically significant correlation was found between the presence of *RET* mutations, both together and when considering M918T alone, and the advanced stage of the disease (p = 0.0025), higher T category (p \< 0.0001), and the presence of both lymph-node (N) (p = 0.0021) and distant metastases (M) (p = 0.0073).Table 4Correlation between Mutational Status of *RET* and *RAS* Genes with Clinical and Pathological Features of the Primary sMTC Cases*RET M918TRET* Other*RAS*Not *RET*/Not *RAS*p Value**Sex**0.1378[a](#tblfn1){ref-type="table-fn"} Female51.2% (22/43)52.8% (19/36)72.5%(29/40)67.9% (19/28) Male48.8% (21/43)47.2% (17/36)27.5% (11/40)32.1% (9/28)Age at diagnosis (mean ± SD) (years)49.43 ± 13.9355.67 ± 14.3255.81 ± 15.4458.84 ± 15.700.0779[b](#tblfn2){ref-type="table-fn"}**Primary/metastases**0.1609[a](#tblfn1){ref-type="table-fn"} Primary74.1% (43/58)83.7% (36/43)90.9% (40/44)84.8% (28/33) Metastases25.9% (15/58)16.3% (7/43)9.1% (4/44)15.2% (5/33)**Outcome\<0.0001**[a](#tblfn1){ref-type="table-fn"} Disease-free26.3% (10/38)66.7% (20/30)61.8% (21/34)77.3% (17/22) Biochemical7.9% (3/38)6.7% (2/30)29.4% (10/34)9.1% (2/22) Metastatic/dead65.8% (25/38)26.6% (8/30)8.8% (3/34)13.6% (3/22)**Stage0.0001**[a](#tblfn1){ref-type="table-fn"} I18.9% (7/37)46.9% (15/32)62.5% (25/40)70.8% (17/24) III81.1% (30/37)53.1% (17/32)37.5% (15/40)29.2% (7/24)**T Categories\<0.0001**[a](#tblfn1){ref-type="table-fn"} T1+T237.1% (13/35)72.7% (24/33)90.0% (36/40)83.3% (20/24) T3+T462.9% (22/35)27.3% (9/33)10.0% (4/40)16.7% (4/24)**Lymph-node metastasis (N**)**0.0021**[a](#tblfn1){ref-type="table-fn"} N030.6% (11/36)54.5% (18/33)66.7% (26/39)75.0% (18/24) N169.4% (25/36)45.5% (15/33)33.3% (13/39)25.0% (6/24)**Distant metastasis (M)0.0073**[a](#tblfn1){ref-type="table-fn"} M077.8% (28/36)90.6% (29/32)97.5% (39/40)100.0% (24/24) M122.2% (8/36)9.4% (3/32)2.5% (1/40)0 (0/24)[^8][^9][^10]

In contrast to *RET*-mutated cases, *RAS*-mutated sMTC cases were significantly associated with a better outcome (p = 0.001), a lower stage of disease (p = 0.0037), and lower T category (i.e., T1/T2) (p = 0.0015), but no correlation was observed between the presence of *RAS* mutation and other epidemiological and pathological features ([Table 5](#tbl5){ref-type="table"}).Table 5Association of *RAS*-Mutated sMTC Cases and Clinical and Pathological Features*RAS+RAS*-p Value**Sex**0.089[a](#tblfn3){ref-type="table-fn"} Female72.5% (29/40)56.4% (62/110) Male27.5% (11/40)43.6% (48/110)**Age at diagnosis (mean ± SD)**55.81 ± 15.4458.84 ± 15.700.571[b](#tblfn4){ref-type="table-fn"}**Outcome0.0003**[a](#tblfn3){ref-type="table-fn"} Disease-free61.8% (21/34)52.2% (47/90) Biochemical29.4% (10/34)7.8% (7/90) Metastatic/dead8.8% (3/34)40% (36/90)**Stage0.0037**[a](#tblfn3){ref-type="table-fn"} I + II62.5% (25/40)41.5% (39/94) III + IV37.5% (15/40)58.5% (55/94)**T Categories0.0015**[a](#tblfn3){ref-type="table-fn"} T1+T290.0% (36/40)62.4% (58/93) T3+T410.0% (4/40)37.6% (35/93)**Lymph-node metastasis (N)**0.0857[a](#tblfn3){ref-type="table-fn"} N066.7% (26/39)49.5% (46/93) N133.3% (13/39)50.5% (47/93)**Distant metastasis (M)**0.107[a](#tblfn3){ref-type="table-fn"} M097.5% (39/40)88.2% (82/93) M12.5% (1/40)11.8 (11/93)[^11][^12][^13]

A strong correlation was also found between the presence of *RET* mutations and a worse patient outcome (p \< 0.0001), and the survival of Kaplan-Meier curves confirmed that patients with sMTC harboring the *RET* mutation had a higher rate of cancer-related deaths than patients harboring *RAS* mutations (log rank = 4.41; p = 0.035) ([Figure 2](#fig2){ref-type="fig"}).Figure 2Survival in *RET-* and *RAS-*Mutated sMTC CasesKaplan-Meier curves showing survival in patients with sMTC harboring *RET* mutations or *RAS* mutations. The difference in the curves was statistically significant (log rank = 4.41; p = 0.035) and demonstrated that *RET*-positive cases have a higher probability to die of the disease.

Correlation of the Variant Allele Frequency Value with the Tumor Size and Outcome of the Patients {#sec2.4}
-------------------------------------------------------------------------------------------------

The overall mean VAF of the mutations found was 35.1% (median, 30.2; range, 4.4--95.2). However, a big difference in VAF was observed among different cases with the lowest VAF observed in the rare and uncommon alterations ([Table S1](#mmc1){ref-type="supplementary-material"}). According to the VAF, we could hypothesize the role of the mutations, especially in those cases with more than one alteration: the mutation with the greatest VAF would likely be the driver mutation ([@bib24]).

As shown in [Figure 3](#fig3){ref-type="fig"}, panel A1, when we compared in 95 patients with primary tumor the VAF value of the driver mutation, any type, with the sMTC tumor size (in centimeters), we observed that larger tumors harbored mutations with a higher VAF value (p \< 0.0001). However, when we performed the same analysis in subgroups according to the type of mutation, the correlation was confirmed in the subgroups of *RET*-mutated cases, either when all *RET* ([Figure 3](#fig3){ref-type="fig"}, panel A2) or only *RET* M918T-mutated cases were considered ([Figure 3](#fig3){ref-type="fig"}, panel A3) (p \< 0.0001 and p = 0.0013, respectively) but not in the subgroup harboring *RAS* mutations ([Figure 3](#fig3){ref-type="fig"}, panel A4).Figure 3Correlation of the Variant Allele Frequency with Tumor Size and Outcome of Patients with sMTC(A) Correlation between the tumor size (cm) and VAF of the driver mutation in sMTC. The comparison considered all mutations (A1), only *RET* mutations (A2), only the *RET* M918T mutation (A3), and only *RAS* mutations (A4). In all cases, except *RAS*-mutated cases, a statistically significant difference was observed (A1: p \< 0.0001; A2: p \< 0.0001; A3: p = 0.0013; A4: p = ns).(B) Correlation between the VAF value (%) of the driver mutations and outcome of patients when considering all mutations (B1), only *RET* mutations (B2), and only *RAS* mutations (B3). The differences between the outcome categories were significant between disease-free and metastatic patients in the former two cases (B1: p = 0.003; B2: p = 0.0047; ANOVA), whereas no difference was observed considering only *RAS* mutations (B3: p = ns). Data are represented as mean ± SEM.

Analyzing 103 patients, a higher VAF value of the driver mutation was also correlated with a worse outcome of the patients, as demonstrated by a significantly higher VAF value in patients with metastatic disease with respect to disease-free patients, both when considering all cases with any type of mutation (p = 0.003) ([Figure 3](#fig3){ref-type="fig"}, panel B1) and when analyzing the subgroup with only *RET* mutations (p = 0.047) ([Figure 3](#fig3){ref-type="fig"}, panel B2). By contrast, this correlation was not found in the subgroup with only *RAS*-positive cases ([Figure 3](#fig3){ref-type="fig"}, panel B3).

Discussion {#sec3}
==========

In recent years, the introduction of NGS techniques has revolutionized research and the diagnosis of many diseases, including endocrine diseases ([@bib30]). In particular, cancer research was hugely improved by this high-throughput techniques, being able to sequence large genome and transcript portions and increasing the probability of discovering novel mutations, especially in less frequently studied genes ([@bib3], [@bib22]).

Several studies have been performed in MTC, both employing WES ([@bib1], [@bib8]) and targeted sequencing with specific panels of gene mutations ([@bib19], [@bib21], [@bib35], [@bib41]). In summary, these studies confirmed the role of *RET* and *RAS* somatic mutations as main drivers in the pathogenesis of sMTC; on the other hand, very few alternative genetic alterations have been discovered, still leaving a rather large portion of cases negative for common somatic gene alterations.

In the present study, we characterized 181 sMTCs by NGS targeted sequencing, and this series represents, to our knowledge, the largest analyzed so far. For this purpose, we designed a custom gene mutational panel that includes all amplicons covering the entire coding region of the *RET*, *HRAS*, *KRAS*, and *NRAS* genes that are known to be involved in C-cell tumorigenesis ([@bib10]) and all the known gene alterations involved in follicular thyroid cancer tumorigenesis ([@bib28], [@bib29]).

Our data showed that 55.8% of cases harbored *RET* genetic alterations, confirming that *RET*, particularly the M918T mutation, is the main driver oncogene in sMTC. The second main driver oncogene has been confirmed to be *RAS*, particularly *HRAS* and *KRAS* genes, which were altered in 24.3% of sMTC cases. Only a small subgroup, representing only 1.6% of cases, showed other types of uncommon mutations whose driver role remains unclear. According to these results, the prevalence of complete negative cases in our series was narrowed to 18.3% of cases ([Figure 1](#fig1){ref-type="fig"}), which increased up to 19.9% if we include the subgroup with the uncommon mutations. In agreement with the results of other two studies ([@bib1], [@bib8]), also in our hands the WES was unable to identify other recurrence mutations that could further reduce this subgroup of negative cases. It is conceivable that for these cases other types of genetic and/or epigenetic alterations can play a role.

Compared with previous data obtained analyzing sMTC by Sanger direct sequencing ([@bib10], [@bib14]), we obtained an overall higher number of mutated cases, especially for *RAS* positive cases and, at the same time, we reduced the negative or "mutational orphan" sMTC cases. These results strongly support the use, whenever possible, of deep-sequencing techniques whose sensitivity is significantly higher than that of Sanger sequencing; this is a very important aspect to address, especially in metastatic patients who could benefit from targeted therapy whose choice largely depends on the knowledge of mutational status ([@bib37]).

In our series, most cases harbored single mutually exclusive alterations (89.2%), whereas only a small portion of cases (7.4%) harbored multiple somatic mutations ([Table 1](#tbl1){ref-type="table"}), demonstrating that, genetically, sMTC is a rather stable tumor similar to what has been shown for papillary thyroid carcinoma ([@bib6]). Moreover, according to the VAF values in the mutations, 9/11 cases harboring multiple somatic mutations showed a higher VAF of the *RET* mutation than that of the additional mutations, thus suggesting the driver role of *RET* also in these heterogeneous cases. It is noteworthy that, in two of four cases with two simultaneous *RET* mutations ([Table 1](#tbl1){ref-type="table"}, cases 41 and 132), the VAF was the same. This finding, combined with the observation that the mutations were closely mapping in *--cis* within the same sequencing read, indicates that they might be the result of a single simultaneous mutational event in a single allele of the same cell and not truly heterogeneous mutations, thus reducing the percentage of "true" heterogeneous cases to 6.5% of sMTC.

In some cases, the VAF observed in additional mutations was rather low and, in several cases, they represented "novel" mutations never described before and with an uncertain pathogenic role ([Table 2](#tbl2){ref-type="table"}). The meaning of these mutations is unknown, but being aware of their presence can be relevant for the follow-up of the patients because, if selected, these mutations could be responsible for acquired resistance during therapy with kinase inhibitors ([@bib5], [@bib9]), and their presence should not be overlooked.

We also found five cases in which a germinal mutation of key genes in thyroid tumorigenesis was also present and whose real pathogenic role is unclear ([Table 1](#tbl1){ref-type="table"}). These five alterations have been already reported in the dbSNP database, although VAF \<0.01 excludes them as common SNPs ([Table 2](#tbl2){ref-type="table"}). The rarity of these alterations in the normal population suggests some pathogenic role for the tumor ([@bib24]), although *in silico* predictive scores describe only some of them as pathogenic. In particular, two of them (i.e, *KRAS* A130V and *PPM1D* K469E) have been described as non-pathogenic/neutral alterations ([@bib34], [@bib39]). Even less is known about the new somatic indel mutation (i.e., *RET* c.1894_1902delGAGCTGTGC; p.E632_C634del) that has never been described previously ([Table 2](#tbl2){ref-type="table"}).

Among cases presenting multiple mutations we did not find any difference in terms of number and type of mutations when comparing cases in which we analyzed the primary tumor tissues with in which we analyzed the metastatic lesions. The most recurrent additional mutation (5/181, 2.8%) observed in our series was the *MET* T1010I point mutation that was present at either the somatic or the germinal level ([Table 3](#tbl3){ref-type="table"}), as demonstrated also by the VAF (i.e., approximately 50% when germinal and less than 20% when somatic). In our series, *MET* T1010I was always associated to a driver mutation either in *RET* or *RAS* gene. The T1010I mutation is located in exon 14 of the *MET* gene encoding for the juxtamembrane portion of the tyrosine kinase ([@bib12]) and exon 14 alterations, which are described in different tumor types, might be crucial for activation of the *MET* oncogene ([@bib36]). Germinal and/or somatic *MET* T1010I mutations have been described in several tumor types ([@bib12]), including thyroid tumors ([@bib40]). In this last study, 104 thyroid tumors were analyzed and somatic or germline *MET* T1010I mutations were found in 7% of samples: particularly, 1/12 (8.3%) sMTC harbored a germline *MET* T1010I. We also found either somatic (4/5) or germline (1/5) *MET*T1010I-mutated cases, but all of them were characterized by the presence of another mutation likely driving the tumoral transformation. In general, the role of this mutation in cancer is not fully understood, and conflicting results exist, especially in other human tumors. As suggested for other human cancers ([@bib27]), a predisposing role of *MET* T1010I, especially when present at the germline level, might be hypothesized also for sMTC.

Other than describing the oncogene mutations involved in the pathogenesis of sMTC, we also compared the mutational status of these tumors with the clinical and pathological features of patients ([Table 4](#tbl4){ref-type="table"}). The presence of *RET* mutations and, in particular, the M918T was confirmed to be significantly associated with a worse outcome, a higher tumoral staging, a higher T category, and the presence of lymph-node and distant metastases. Moreover, when we compared the survival Kaplan-Meier curves of patients with sMTC with *RET* or *RAS* somatic mutations, a significantly lower percentage of surviving patients in the *RET*-positive cases was found. These results confirmed in a much larger series our previously reported data ([@bib10], [@bib14]) and those recently collected in a meta-analysis summarizing the clinical significance of the mutational status in MTC ([@bib38]).

Simultaneously, we observed that *RAS*-positive cases were significantly associated with a better outcome, a lower tumor staging, and a lower rate of T categories than *RET*-positive cases, and, also when compared with the *RAS* negative cases, independent from the presence of *RET* mutation ([Table 5](#tbl5){ref-type="table"}). With these results, we confirmed that sMTC with *RAS* mutations have, in general, a less aggressive phenotype and a better prognosis as we previously observed ([@bib10]) and herein, as definitively demonstrated by the virtually 100% rate of survival of patients harboring *RAS* mutations ([Figure 2](#fig2){ref-type="fig"}).

Compared with previous studies, using the NGS approach, we could also evaluate the VAF value, adding a parameter that it is not possible to evaluate using Sanger direct sequencing. The mutated allele abundance has been demonstrated to be a prognostic factor itself in tumors, including PTC, in which a higher *BRAF* V600E VAF predicts a poorer outcome ([@bib18]). Our results demonstrated that, also in this series, larger tumors not only are more frequently *RET* mutated but also have a higher VAF that corresponds to a higher percentage of mutated cells. This observation suggests that the presence of a *RET*-mutated allele, particularly M918T, confers a growth advantage and results in larger clonal tumors. These findings are also in line with our previous observation of a lower rate of *RET* M918T mutation in micro-MTC that, when mutated, likely harbored a much lower VAF of the *RET* mutation not detectable with the traditional Sanger sequencing ([@bib33]). Moreover, we demonstrated that a higher VAF correlated with a poorer prognosis, both when considering all mutations and when considering only *RET* mutations. According to these findings, VAF may be included in the list of bad prognostic markers in the subgroup of *RET*-mutated sMTC cases.

By contrast, *RAS*-mutated tumors appear to be clonal also in smaller tumors and no difference in the outcome of patients was observed compared with the *RAS*-mutated allele abundance. Based on this observation, we can hypothesize that two different sMTC types, in terms of both development and aggressiveness, might exist (i.e., *RET*-like and *RAS*-like) and further studies are needed to confirm this hypothesis.

Finally, we studied most of the sMTC for the presence of mutations in the *TERT* gene promoter hotspots (C228, C250), and, conversely, regarding what happens to other thyroid neoplasms ([@bib2]), *TERT* promoter mutations in C228 and C250, at least in our study, do not play any role in the pathogenesis and/or progression of sMTC.

In conclusion, in the present study, that included the largest series of sMTC studied so far by NGS, we confirmed that *RET* and *RAS* gene alterations are the main actors in driving the development of this rare human tumor. Moreover, we reinforced the concept that *RET*-mutated cases have a more aggressive phenotype and a poorer prognosis, particularly when the VAF is higher, so that this parameter can be considered a new marker of a worse prognosis in *RET*-mutated sMTC. At the same time, we demonstrated that *RAS*-mutated cases have a better outcome than *RET*-mutated cases. Finally, a lower-than-expected percentage of sMTC cases are still orphans of a recognized genetic driver, and further studies for alternative mechanisms of tumor transformation need to be performed.

Limitations of the Study {#sec3.1}
------------------------

The main limitation of this study is that we used a custom targeting sequencing panel including a large series of genes involved in thyroid cancer pathogenesis that failed in providing evidence of strong alternative mechanisms of pathogenesis besides *RET* and *RAS* mutations. Although in some cases WES analysis was also performed, the possibility that other alterations may be involved cannot be completely ruled out with this study.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#sec7}
==========================

For the following novel mutation a submission to COSMIC DATABASE has been requested and an identifier **COSP47106** has been generated by COSMIC as a proof of successful data submission.*RET* c.2774A\>C; p.D925A*RET* c.890G\>A; p.R297H*NRAS* c.53C\>T; p.A18V*RET* c.2710T\>C; p.S904P*RET* c.1894_1902delGAGCTGTGC; p.E632_C634del*RET* c.3071C\>T; p.S1024F*EIF1AX* c.404G\>C; G135A*CHK2* c.341G\>A; W114∗
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